Pharsight

Ciprodex patents expiration

CIPRODEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9402805 NOVARTIS Method of treating middle ear infections
Sep, 2022

(1 year, 20 days ago)

US9149486 NOVARTIS Method of treating middle ear infections
Sep, 2022

(1 year, 20 days ago)

US9345714 NOVARTIS Method of treating middle ear infections
Sep, 2022

(1 year, 20 days ago)

US8846650 NOVARTIS Method of treating middle ear infections
Jun, 2025

(1 year, 8 months from now)

Ciprodex is owned by Novartis.

Ciprodex contains Ciprofloxacin; Dexamethasone.

Ciprodex has a total of 4 drug patents out of which 3 drug patents have expired.

Expired drug patents of Ciprodex are:

  • US9402805
  • US9149486
  • US9345714

Ciprodex was authorised for market use on 18 July, 2003.

Ciprodex is available in suspension/drops;otic dosage forms.

Ciprodex can be used as treatment of acute otitis media; treatment of acute otitis externa, treatment of acute otitis media.

The generics of Ciprodex are possible to be released after 04 June, 2025.

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media; Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

How can I launch a generic of CIPRODEX before it's drug patent expiration?
More Information on Dosage

CIPRODEX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic